AI Science Tracker

Eindhoven University of Technology

1 discovery from 2026

Discoveries

Joint molecular modeling identifies seven low-micromolar kinase hits beyond its training chemistry

A joint molecular model combined bioactivity prediction and molecule reconstruction to estimate how unfamiliar a candidate structure was to its training distribution. In a prospective screen of commercial compounds against PIM1 and CDK1, unfamiliarity-informed selection led to seven compounds with low-micromolar potency and limited similarity to training molecules. The authors also evaluated the metric across 33 experimentally labelled bioactivity datasets.

Technology: Joint molecular model (JMM): semi-supervised molecular property-prediction and reconstruction model using a SMILES encoder; reconstruction loss defines the unfamiliarity score

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The authors also evaluated the metric across 33 experimentally labelled bioactivity datasets. The reported wet-lab candidate assays directly test the molecular-model predictions within the study.
  • Still unknown: The kinase finding is a prospective in-vitro hit-identification result, not evidence of therapeutic efficacy. Seven low-micromolar hits were reported across PIM1 and CDK1; CDK1 was described as independent of the study’s earlier dataset analysis. The study screened only a small selected set per target after computational ranking. It does not establish the unfamiliarity measure as universally superior or demonstrate animal or clinical benefit.
  • AI role: The model used reconstruction-based unfamiliarity alongside predicted bioactivity and prediction uncertainty to rank molecules for a prospective virtual screen. Researchers tested selected commercial compounds against PIM1 and CDK1; seven compounds showed low-micromolar potency. AI supported prioritization and selection, while wet-lab assays established activity.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13109061/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.